Medical Disclaimer
- Educational Only: Not for clinical decision-making.
- Verify Information: Always consult protocols and authoritative sources.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.
Bedside Snapshot
- Core dose: Nebulizer 2.5–5 mg every 20 min × 3 for severe bronchospasm (can give continuous 10–15 mg/h); MDI 4–8 puffs every 20 min × 3; hyperkalemia 10–20 mg nebulized
- Onset/duration: Onset 5–15 min; peak effect 60–90 min; duration 3–6 hours
- Key danger: Tachycardia, tremor, and hypokalemia (especially with high/repeated doses); use caution in cardiac disease or arrhythmias
- Special: Selective β2-agonist bronchodilator; can combine with ipratropium for severe exacerbations; causes intracellular K⁺ shift (useful adjunct in hyperkalemia); less effective if patient not breathing deeply
Brand & Generic Names
- Generic Name: albuterol (U.S.); international name: salbutamol
- Brand Names: Proventil HFA, Ventolin HFA, ProAir HFA/RespiClick/Digihaler, AccuNeb
Medication Class
Short-acting β2-adrenergic agonist (SABA); bronchodilator
Pharmacology
Mechanism of Action:
- Selective β2-receptor agonism in airway smooth muscle increases cAMP (via adenylyl cyclase → PKA), producing bronchodilation.
- Reduces mediator release from mast cells; may enhance mucociliary clearance.
- Selectivity is dose-dependent; high systemic exposure can stimulate β1 receptors (tachycardia/palpitations).
Pharmacokinetics:
- Onset: Inhaled onset 5–15 min; peak 60–90 min; duration about 3–6 h.
- Half-life: ~3–8 h (inhaled/PO range)
- Protein binding: ~10%
- Metabolism: Hepatic metabolism (predominantly sulfation to inactive metabolite)
- Elimination: Renal elimination of parent and metabolites
- Metabolic effects: Causes intracellular K⁺ shift (transient decrease in serum potassium)
Indications
- Acute bronchospasm in asthma or COPD exacerbations
- Prevention of exercise-induced bronchospasm
- Adjunct in hyperkalemia to temporarily lower serum potassium while definitive therapies are given
Conditions Treated
- Asthma (acute exacerbation)
- Chronic obstructive pulmonary disease (COPD) exacerbation
- Exercise-induced bronchospasm
- Hyperkalemia (adjunct therapy, off-label)
Dosing & Administration
Available Forms:
- Metered-dose inhaler (MDI): 90 mcg per actuation
- Dry powder inhaler (DPI) - RespiClick/Digihaler: 90 mcg per inhalation
- Nebulizer solution: 0.083% (2.5 mg/3 mL), 0.5% (2.5 mg/0.5 mL), unit-dose 0.63 or 1.25 mg/3 mL
Adult Dosing:
| Route / Indication | Dose | Notes |
|---|---|---|
| MDI (Quick-relief) | 2 puffs every 4–6 h as needed | Maximum 12 puffs/day |
| MDI (Severe flare) | 4–8 puffs via spacer every 20 min for up to 3 doses | Use with spacer for better delivery |
| DPI (RespiClick/Digihaler) | 2 inhalations every 4–6 h as needed | Maximum 12 inhalations/day |
| Nebulizer (Moderate–severe exacerbation) | 2.5–5 mg every 20 min for 3 doses, then 2.5–10 mg every 1–4 h as needed | May use continuous 10–15 mg/h for severe cases |
| Exercise-induced bronchospasm | 2 puffs 15–30 min before activity | Preventive dosing |
| Hyperkalemia (off-label) | 10–20 mg via nebulizer over ~10 min | Onset ~15 min; effect is temporary |
Pediatric Dosing (Nebulized):
- 0.15 mg/kg (minimum 2.5 mg) every 20 min × 3 doses, then as needed
Contraindications
Contraindications:
- Hypersensitivity to albuterol or product components
- Certain DPIs should be avoided in patients with severe milk protein allergy
Precautions:
- Use with caution in ischemic heart disease, arrhythmias, hypertension, hyperthyroidism, diabetes, or seizure disorders
- Frequent need or escalating doses indicate poor control—optimize controller therapy and reassess diagnosis/technique
- May lower serum potassium and increase heart rate; monitor ECG/electrolytes in severe attacks or with high/continuous dosing
Drug Interactions: Nonselective β-blockers may blunt effect; MAOIs/TCAs can potentiate cardiovascular effects; additive hypokalemia with loop/thiazide diuretics; digoxin levels/effects may be altered—monitor as clinically indicated.
Adverse Effects
Common:
- Tremor
- Nervousness
- Tachycardia/palpitations
- Headache
- Throat irritation or cough
Metabolic:
- Hypokalemia
- Hyperglycemia
Serious (but uncommon):
- Paradoxical bronchospasm
- Hypersensitivity reactions
- QT prolongation/arrhythmias
- Lactic acidosis with high or prolonged dosing
Clinical Pearls
MDI vs Nebulizer: MDI with spacer provides bronchodilation comparable to nebulization for many patients; select device based on patient status and logistics.
Moderate–Severe Exacerbations: Use repeated or continuous dosing early, then taper as work of breathing and wheeze improve.
Add Ipratropium: In moderate–severe asthma/COPD exacerbations, add ipratropium to improve airflow and reduce admissions.
Hypoxemic Patients: Run nebulizers on oxygen (about 6–8 L/min) when hypoxemic; closely monitor HR, rhythm, potassium, and—if high doses—lactate.
Levalbuterol Alternative: Consider levalbuterol if tremor or tachycardia is limiting, recognizing clinical differences are often modest.
Hyperkalemia Use: Hyperkalemia response is variable (less reliable in ESRD); combine with insulin/glucose and other temporizing measures.
β-Blocker Interaction: Nonselective β-blockers (e.g., propranolol) may attenuate bronchodilation; consider cardioselective agents if a β-blocker is required.
References
- 1. Papadopoulos, J. (2008). Pocket guide to critical care pharmacotherapy. Humana Press.
- 2. Medscape. (n.d.). Albuterol (Proventil HFA, Ventolin HFA) – drug monograph. Retrieved 2025-11-12, from https://reference.medscape.com/drug/proventil-hfa-ventolin-hfa-albuterol-343426
- 3. DrugBank Online. (n.d.). Albuterol (DB01001). Retrieved 2025-11-12, from https://go.drugbank.com/drugs/DB01001
- 4. Boucher, B. A., Wood, G. C., & Swanson, J. M. (2006). Pharmacokinetic changes in critical illness. Critical Care Clinics, 22(2), 255–271.
- 5. Medscape. (n.d.). Hyperkalemia: Treatment & management. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/240903-treatment